Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Masitinib for the treatment of mild to moderate Alzheimer’s disease
Jaume Folch, Dmitry S. Petrov, Miren Ettcheto, et al.
Expert Review of Neurotherapeutics (2015) Vol. 15, Iss. 6, pp. 587-596
Closed Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

An Inflammation-Centric View of Neurological Disease: Beyond the Neuron
Stephen D. Skaper, Laura Facci, Morena Zusso, et al.
Frontiers in Cellular Neuroscience (2018) Vol. 12
Open Access | Times Cited: 387
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Jaume Folch, Dmitry S. Petrov, Miren Ettcheto, et al.
Neural Plasticity (2016) Vol. 2016, pp. 1-15
Open Access | Times Cited: 258
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Nir Drayman, Jennifer K. DeMarco, Krysten A. Jones, et al.
Science (2021) Vol. 373, Iss. 6557, pp. 931-936
Open Access | Times Cited: 218
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Bruno Dubois, Jesús López‐Arrieta, Stanley Lipschitz, et al.
Alzheimer s Research & Therapy (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 54
Targeting Fyn Kinase in Alzheimer’s Disease
Haakon B. Nygaard
Biological Psychiatry (2017) Vol. 83, Iss. 4, pp. 369-376
Open Access | Times Cited: 143
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 129
Precision pharmacology for Alzheimer’s disease
Harald Hampel, Andrea Vergallo, Lisi Flores Aguilar, et al.
Pharmacological Research (2018) Vol. 130, pp. 331-365
Open Access | Times Cited: 93
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Jiansong Fang, Andrew A. Pieper, Ruth Nussinov, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2386-2426
Open Access | Times Cited: 79
Drug Repurposing for COVID-19: A Review and a Novel Strategy to Identify New Targets and Potential Drug Candidates
Liliana Rodrigues, Renata Bento Cunha, Tatiana Vassilevskaia, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2723-2723
Open Access | Times Cited: 66
Decoding Mast Cell-Microglia Communication in Neurodegenerative Diseases
Jagdeep K. Sandhu, Marianna Kulka
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1093-1093
Open Access | Times Cited: 61
GSK-3β, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways
Stefania Demuro, Rita Maria Concetta Di Martino, José Antonio Ortega, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 9098-9098
Open Access | Times Cited: 61
Role of Mast Cells in Regulation of T Cell Responses in Experimental and Clinical Settings
Daniel Elieh Ali Komi, Korneel Grauwet
Clinical Reviews in Allergy & Immunology (2017) Vol. 54, Iss. 3, pp. 432-445
Closed Access | Times Cited: 72
Fyn Tyrosine Kinase as Harmonizing Factor in Neuronal Functions and Dysfunctions
Carmela Matrone, Federica Petrillo, Rosarita Nasso, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4444-4444
Open Access | Times Cited: 70
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Nurul Husna Ibrahim, Mohamad Fairuz Yahaya, Wael Mohamed, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 63
Potential Repositioning of Anti-cancer EGFR Inhibitors in Alzheimer’s Disease: Current Perspectives and Challenging Prospects
Heba M. Mansour, Hala M. Fawzy, Aiman S. El‐Khatib, et al.
Neuroscience (2021) Vol. 469, pp. 191-196
Closed Access | Times Cited: 47
Alzheimer's Disease: From Mitochondrial Perturbations to Mitochondrial Medicine
Susana Cardoso, Cristina Carvalho, Sónia C. Correia, et al.
Brain Pathology (2016) Vol. 26, Iss. 5, pp. 632-647
Open Access | Times Cited: 60
Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases
Francesco Girolamo, Cristiana Coppola, Doménico Ribatti
Brain Behavior and Immunity (2017) Vol. 65, pp. 68-89
Closed Access | Times Cited: 57
Biomaterials for the Treatment of Alzheimer’s Disease
Darya Hadavi, A.A. Poot
Frontiers in Bioengineering and Biotechnology (2016) Vol. 4
Open Access | Times Cited: 55
The Role of Mast Cells in Alzheimer’s Disease
Yazdani B. Shaik-Dasthagirisaheb, Pio Conti
Advances in Clinical and Experimental Medicine (2016) Vol. 25, Iss. 4, pp. 781-787
Open Access | Times Cited: 54
Protein aggregation in cell biology: An aggregomics perspective of health and disease
Dezerae Cox, Candice Raeburn, Xiaojing Sui, et al.
Seminars in Cell and Developmental Biology (2018) Vol. 99, pp. 40-54
Closed Access | Times Cited: 51
Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2in vitro
Nir Drayman, Krysten A. Jones, Saara‐Anne Azizi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 40
Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer’s disease
Mahmoud Nabawy Mahmoud Khattab, Heba M. Mansour, HalaM Fawzy, et al.
Neural Regeneration Research (2021) Vol. 17, Iss. 9, pp. 1913-1913
Open Access | Times Cited: 40
Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain
Leon Stefanovski, J. Meier, Roopa Pai, et al.
Frontiers in Neuroinformatics (2021) Vol. 15
Open Access | Times Cited: 38
Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model
Levi M. Smith, Rong Zhu, Stephen M. Strittmatter
Neuropharmacology (2017) Vol. 130, pp. 54-61
Open Access | Times Cited: 48
Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer’s Disease
Tengfei Li, Elodie Martin, Yah-se K. Abada, et al.
Journal of Alzheimer s Disease (2020) Vol. 76, Iss. 4, pp. 1339-1345
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top